VRTX Vertex Pharmaceuticals Incorporated

This biotech player is firing on all cylinders.

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 46.9% over the past six months, topping the S&P 500 by 25.5 percentage points.

And there could be more positive developments ahead.

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Maze Therapeutics (NASDAQ:MAZE) shares rose 2. 9% in pre-market trading after CIBC initiated coverage of the clinical-stage biopharmaceutical company with an Outperformer rating and a $50 price target.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.9% to $514.18 per share while the index has gained 14%.

This company has had plenty of setbacks in recent years, but it generally bounces back.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

In August 2026, Vertex Pharmaceuticals announced that Senior Vice President of Finance Jonathan Poole will become Executive Vice President and Chief Financial Officer on January 1, 2027, while Charles F. Wagner Jr. remains Executive Vice President and Chief Operating Officer. This internal promotion, paired with Vertex’s increased external visibility through forums such as the Boston C-Level Technology Leadership Summit, highlights how the company is elevating both its financial leadership...

Vertex Pharmaceuticals (VRTX) has been in focus after presenting at the 18th Annual Boston C-Level Technology Leadership Summit on September 10, where its Chief Digital and Information Officer outlined the group’s technology priorities. Recent trading has been choppy for Vertex Pharmaceuticals, with the share price falling 4.9% over the past week but still showing a 14.6% 90 day share price return and a 32.1% 1 year total shareholder return. This points to momentum that has built over a...

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and President Reshma Kewalramani said at Morgan Stanley’s 24th Annual Healthcare Conferen

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, s

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.

Both companies are approaching milestones that could light a fire under their stocks.

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.

The company has tremendous prospects.

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.

The company had fallen out of investor favor; its recovery was impressive.

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

They could both outperform the market over the medium term, but one appears to have a clear edge.

We'll know a little more about the company's prospects by the end of the year.

Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...